The PRV sale and KRESLADI approval remove near-term financing risk and validate the platform, but the stock's next major catalyst is the FDA alignment on completing the Danon disease pivotal trial, expected in H2 2026. Monitor for the investor webinar and regulatory update on RP-A601 in PKP2-ACM.
Price Chart
Executive Summary
Rocket Pharmaceuticals reported Q2 2026 GAAP net income of $123.2M ($1.09 basic EPS), driven by a $178.2M gain from the sale of its Priority Review Voucher (PRV), compared to a net loss of $68.9M in Q2 2025. Operating loss improved to $46.9M from $71.1M on lower R&D and G&A expenses. The company ended the quarter with $283.7M in cash, extending runway into Q2 2028, and reported positive safety data from the first three Danon disease patients in the pivotal Phase 2 trial of RP-A501.
Key Financial Metrics
Key Facts
- GAAP net income of $123.2M in Q2 2026 vs net loss of $68.9M in Q2 2025, primarily due to $178.2M gain from PRV sale.
- Cash, cash equivalents, and investments of $283.7M as of June 30, 2026, up from $188.9M at Dec 31, 2025, extending runway into Q2 2028.
- All three initial patients in the pivotal Phase 2 trial of RP-A501 for Danon disease completed the safety observation period with no TMA, capillary leak syndrome, or other significant safety concerns.
- KRESLADI (marnetegragene autotemcel) received FDA accelerated approval for severe LAD-I; commercial availability and patient onboarding expected to begin in Q4 2026.
- Operating loss improved to $46.9M from $71.1M year-over-year, driven by lower R&D and G&A expenses.
Financial Impact
Net income of $123.2M vs net loss of $68.9M YoY; cash position strengthened by $94.8M sequentially to $283.7M
Risk Factors
- KRESLADI is a first commercial launch for the company; adoption and reimbursement timelines are uncertain.
- Danon disease pivotal trial completion depends on FDA alignment; any delays or safety signals in additional patients could reset the timeline.
- Operating expenses, while reduced, still consume cash; the company remains pre-revenue from product sales until KRESLADI launches.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-032028 |
| Document: ef20079821_8k.htm | 0001140361-26-032028 |
| Document: 0001140361-26-032028-index-headers.html | 0001140361-26-032028 |
| Document: 0001140361-26-032028-index.html | 0001140361-26-032028 |
| Document: 0001140361-26-032028.txt | 0001140361-26-032028 |
| 8-K Data (Synthetic) | 0001140361-26-032028 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $3.41 $3.35 | ▼ −1.76% | ▼ −3.89% | $2.56 (−24.93%) |
Aug 20, 2026 6w ago | Insider Cluster | $3.48 $3.62 | ▲ +4.02% | ▲ +2.91% | $2.56 (−26.44%) |
Aug 17, 2026 6w ago | Insider Cluster | $3.34 $3.78 | ▲ +13.17% | ▲ +13.37% | $2.56 (−23.35%) |
Aug 13, 2026 7w ago | Insider Cluster | $3.34 $3.48 | ▲ +4.04% | ▲ +6.01% | $2.56 (−23.35%) |
Aug 10, 2026 7w ago | 8-K | $3.50 $3.34 | ▼ −4.57% | ▼ −4.17% | $2.56 (−26.86%) |
Aug 3, 2026 8w ago | 8-K | $3.41 $3.64 | ▲ +6.74% | ▲ +4.72% | $2.56 (−24.93%) |
Jun 30, 2026 13w ago | 8-K | $3.52 $4.07 | ▲ +15.63% | ▲ +15.36% | $2.56 (−27.27%) |
Jun 12, 2026 16w ago | 8-K | $2.75 $3.35 | ▲ +21.82% | ▲ +21.15% | $2.56 (−6.91%) |
May 26, 2026 18w ago | Insider Cluster | $2.99 $2.92 | ▼ −2.34% | ▼ −2.81% | $2.56 (−14.38%) |
May 7, 2026 21w ago | Insider Cluster | $3.25 $2.96 | ▼ −8.92% | ▼ −9.89% | $2.56 (−21.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access